Is vaping safer than smoking?

For a current daily smoker, switching to vaping is almost certainly less harmful than continuing to smoke — tobacco combustion produces hundreds of toxic and carcinogenic compounds that vaping does not. That is not the same as saying vaping is safe. The long-term health effects of inhaled aerosol from e-cigarettes — nicotine, flavourings, heating-coil byproducts, ultra-fine particles — are still being established, because the devices have not been in widespread use for long enough to generate decades-long outcome data. For someone who has never smoked, taking up vaping represents an exposure that did not previously exist — and that distinction is clinically important when thinking about population-level impact.

My teenager is vaping. What should I do?

This is worth raising with your GP rather than managing only at home. Nicotine dependence in adolescence is concerning because the developing brain is more sensitive to nicotine's effects on reward circuitry, and early-onset dependence is associated with harder cessation later in life. A GP can assess the degree of dependence, discuss evidence-based options, and refer to a youth-appropriate cessation service if needed. At home, conversations framed around addiction risk — rather than rule-following — tend to be more productive with teenagers than moral arguments alone.

Vaping tripled as smoking fell — and that's not a win

What just happened

Australia’s Health 2026 — the AIHW’s biennial national health report — contains a statistic that deserves more attention than it has received in the broader coverage.

Between 2019 and 2022–23, daily tobacco smoking in Australia fell from 11% to 8.3%. This is genuine progress: tobacco kills roughly 21,000 Australians per year, and declining prevalence represents a real reduction in preventable death and disease across the population.

In the same period, daily e-cigarette use rose from 1.1% to 3.5%. That is a tripling of the vaping population in four years — an increase of approximately 2.4 percentage points, running almost parallel to the 2.7-point drop in daily smokers.

The instinct is to net these figures off and declare a public health win. Fewer people are using the more dangerous product; some of those are using a less dangerous one. That framing is not wrong — but it is incomplete. Because the vaping rise is not simply a recategorisation of former smokers who have found a less harmful delivery mechanism. A substantial portion of the people now vaping daily are people who would not, without access to vaping products, have taken up nicotine at all.

The both-and

For smokers who switch, vaping reduces harm

The least contested claim in this space is also the most clinically important for general practice: for a current daily smoker, switching to vaping is substantially less harmful than continuing to smoke. The TGA acknowledges that tobacco combustion generates hundreds of toxic and carcinogenic compounds — carbon monoxide, benzene, formaldehyde, polycyclic aromatic hydrocarbons — that vaping does not. The cardiovascular, respiratory, and oncological burden of long-term tobacco smoking is documented across decades of research. The equivalent evidence for vaping is not yet available, because the devices have not been in widespread use for long enough.

This is the kernel of truth that should anchor any clinical conversation with a patient who currently smokes and is considering switching: the comparison that matters is not vaping versus nothing. It is vaping versus continuing to smoke. And for that comparison, the evidence strongly favours switching.

The RACGP acknowledges the potential of nicotine vaping as a cessation tool for current smokers through its smoking cessation guidance, while noting that evidence for vaping as a cessation intervention remains less robust than for licensed pharmacotherapies — nicotine replacement therapy, varenicline, or bupropion — which have more extensive randomised trial evidence and established safety profiles.

The new-user problem changes the equation at population level

The difficulty with using harm reduction as the framing for all vaping policy is that it does not describe what is actually happening in the population data. E-cigarette uptake has been most marked in younger Australians — precisely the demographic that had already largely rejected cigarette smoking. For this group, vaping is not harm reduction relative to smoking. It is harm creation relative to not using nicotine at all.

If a significant cohort of Australians enters their 30s with nicotine dependence they would not have developed without access to vaping products, the population-level equation looks different to the individual clinical calculus. The AIHW figures document the scale of that shift: 3.5% of Australians now using e-cigarettes daily represents roughly 900,000 people. Many of them did not stop smoking to get there.

Australia’s prescription model is right — enforcement is the gap

Australia moved to a prescription-only model for therapeutic vaping in late 2023, restricting legal sale to pharmacies with a valid prescription. The TGA continues to monitor the regulatory environment and has issued repeated warnings about illicit products — sold without prescription through convenience stores, tobacconists, and online — that contain substances not listed on the label, including synthetic cannabinoids and other compounds presenting unknown and potentially serious risks.

The prescription model is the correct policy direction. It attempts to maintain genuine access for smokers who might benefit from a vaping-based cessation strategy, while gatekeeping nicotine uptake among those without a clinical indication. The problem is the gap between the model and its implementation: while illicit vaping products remain cheap and broadly accessible, the prescription pathway functions as a friction point for the patient who might legitimately benefit, while doing little to impede the 16-year-old using an illicit device purchased for $10 from a convenience store.

This is not a reason to abandon the prescription model. It is a reason to substantially increase enforcement resourcing and for state and territory governments to treat illicit nicotine supply with the same seriousness they bring to other forms of illicit drug supply.

My two cents

The AIHW data is a prompt for conversations worth having in the consult room — not just about patients’ own habits, but about what is happening in their households.

For a 45-year-old woman with a teenager at home, vaping is already a clinical topic even if it hasn’t been raised yet. The AIHW figures document the population prevalence; the clinical question for any individual adolescent is whether dependence has developed and what options are available. That is a conversation worth initiating before it becomes urgent.

For the same woman who gave up cigarettes five years ago and has since started vaping “just occasionally, for stress”: that warrants a clinical question too. Not a judgement. A question about whether the nicotine dependence has been resolved or simply relocated, what the current frequency actually is, and whether there are cessation options that haven’t yet been tried.

The harm is shifting. That is not the same as the harm disappearing.

Verdict: yes — worth knowing about.

Sources cited

AIHW — Australia’s Health 2026, key findings. https://www.aihw.gov.au/reports/australias-health/australias-health-2026
TGA — Vaping in Australia: regulation and consumer information. https://www.tga.gov.au/resources/resource/general/vaping-australia
Cochrane Review — Electronic cigarettes for smoking cessation (2024). https://www.cochrane.org/CD010216/TOBACCO_electronic-cigarettes-for-smoking-cessation